Jerini AG Reaches Agreement to Sell JPT Peptide Technologies GmbH to TheraCode GmbH
Jerini AG has reached an agreement to sell its wholly-owned subsidiary, JPT Peptide Technologies GmbH to TheraCode GmbH, Mainz, a wholly-owned subsidiary of BioNTech AG, Mainz. Under the terms of the agreement, TheraCode GmbH will pay Jerini AG a purchase price of approximately € 5 million in cash. The sale of JPT Peptide Technologies GmbH to TheraCode GmbH is a further achievement in the implementation of Jerini AG's strategic decision published on October 10, 2008 to divest all non-strategic businesses and to focus on the core business Firazyr.
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.